IPOs via Xetra offer companies numerous advantages. Investors, companies and lead managers can follow the price determination process in the Xetra order book. Liquidity is bundled from the outset on Xetra and the price determination process can be broadcast live on the internet or on television.
"We welcome Epigenomics as the first biotechnology IPO in the Prime Standard," said Rudolf Ferscha member of the Executive Board of Deutsche Börse AG and Chairman of the Board of Management of the Frankfurt Stock Exchange. "The company will now have access to one of the most efficient and high-performance capital markets in the world via the world's largest stock exchange network." Ferscha pointed out that companies and investors can already find the largest peer group of small and medium-sized biotechnology companies in Europe on the Frankfurt Stock Exchange.
39 pharmaceutical and healthcare companies with a market capitalization of around €25 billion are now listed on the Prime Standard of the Frankfurt Stock Exchange; including Epigenomics, this includes 14 biotechnology companies, 7 pharmaceutical and healthcare companies, 12 medical technology companies and 7 pharmaceutical companies.
The shares were initially priced at €9. The banking consortium included Morgan Stanley as global coordinator and bookrunner, Lehman Brothers International (Europe) as joint lead manager and DZ BANK AG Deutsche Zentral-Genossenschaftsbank as co-lead manager.
